Let the markets tell you where it wants to go & Trade Without FEAR
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Gilead Sciences to Present at the RBC Capital Markets 2015 Healthcare Conference on Wednesday, February 25
http://www.businesswire.com/news/home/20150224006403/en/Gilead-Sciences-Present-RBC-Capital-Markets-2015#.VO05bfnF_h4
8:30 am Eastern Time tomorrow
GILD
LGF +10% move on the day. Very nice. Now I know why this was still nearly 100% institutionally owned despite getting beating down.
Stock goes down very slowly and up like a rocket.
Lionsgate Enters Into Stock Exchange Agreement with Affiliates of John Malone:
http://www.prnewswire.com/news-releases/lionsgate-enters-into-stock-exchange-agreement-with-affiliates-of-john-malone-300034332.html
LGF hit $32.28 high in the pre-market session on this news.
Gilead Sciences to Present at Two Upcoming Investor Conferences
http://www.marketwatch.com/story/gilead-sciences-to-present-at-two-upcoming-investor-conferences-2015-02-09?reflink=MW_news_stmp
First at the the 17th Annual BIO CEO & Investor Conference on Feb 10th and second at the the 2015 Leerink Global Healthcare Conference on Feb 11th both in New York and will be available via a live webcast at the company’s Investors page at:
http://www.gilead.com/investors
Wonder how a Credit Suisse neutral rating with a price target +15% above market price equal a -2.4% selloff from current price?
The median analyst price target on GILD is still $118 even with today's CS change:
https://www.flashratings.com/stocks/1046-GILD?in=true
It wasn't the Suisse downgrade that pushed GILD in the red today as the financial media on CNBC was implying this afternoon.
That downgrade was published before the market open and GILD dipped and ripped holding up until well after lunch. Then the algos hit the sell button again on all the Index Funds after news of S&P Greece downgrade broke.
Overlaying the SPY and IBB intraday charts with the GILD intraday one min tells the real story. These broad market auto selloffs are the best times to buy, imo.
I agree, by next quarters results, they will be reversing their stories and suddenly talk about how smart it was for Gilead management to competitively price their product capturing the greater market share of patients.
The street got it so wrong regarding the discounts. Market would have reacted just as extreme, if not more so, had they made a decision to keep their drug priced at a premium and only got a smaller amount of providers on-board as a result. Then the story would have been that Gilead management has locked itself out of the market by pricing their drug too high.
GILD
Cigna signs exclusive Harvoni deal:
http://www.streetinsider.com/Press+Releases/Cigna+Signs+Agreement+with+Gilead+to+Improve+Affordability+of+Hepatitis+C+Treatment+for+Customers+and+Clients/10228617.html
Add Cigna to the list as of today.
Yeah, KITE flys easily like most low float biotechs. $5+ intraday moves are not uncommon on this one.
Today was a good day to scoop up discounted bios.
GILD traded over 70 million total volume on the last big gap down on Dec 22nd and an additional 60 million+ the following session before returning to normal.
That was an -11% gap down with an additional -10% downside the following day before it found a bottom in the $85's all on pure speculation of something that never actually happened.
The funny part of all this is how the fundamental reason stated for the December drop was the exact opposite of the reasons stated for today's drop in price.
However, I don't expect it to fall quite as severe this time around now that they have the lions share of Hep-C coverage as well as a dividend yield on on their stock. What they do lose to discounts, they make up in volume, imo.
Another exaggerated GILD selloff after hours. Knee jerk reaction, imo.
GILD opened lower after their last Quarterly Report was released October 28th after hours, only to rally to new all time highs two days later.
First the bears say Harvoni was too expensive after Express Scripts went with cheaper AbbVie alternative in December. Now they're saying it's too cheap after discounts, lol. Can't win either way.
$2.43 EPS vs $2.17 estimated
$7.3 billion in Revenue(+134.0% Y/Y) beating estimated by $580 million
$2.1 billion Harvoni sales in Q4 alone.
Quarterly Dividend and Share Buyback Program announced. What's not to like?
Buying any dip here tomorrow.
BBRY sure is trading like there's some kind of deal in the works. See if the short interest decreases significantly by the end of the month.
Tempted to dip a toe in here. $11 break on high volume and I'll jump in with both feet.
Gilead’s John Martin Named Morningstar CEO of 2014:
http://blogs.barrons.com/stockstowatchtoday/2015/01/21/gileads-john-martin-named-morningstar-ceo-of-2014/?mod=yahoobarrons&ru=yahoo
Merck to pull hep C drug off U.S. market:
http://seekingalpha.com/news/2233256-merck-to-pull-hep-c-drug-off-u-s-market
GILD
GILD - 01/16 IMS Script Numbers:
http://gileadscienceshareholder.blogspot.de/2015/01/ims-0116-harvoni-scripts-were-7119.html
Someone posted these under the following SA article:
http://seekingalpha.com/article/2827136-gilead-a-bullish-update?auth_param=tbm89:1abiof1:a8d16fc51455d5da60d898df70fb4788&uprof=44&dr=1
Breaking: Aetna backs Gilead's hepatitis C treatment and gets discount:
http://www.reuters.com/article/2015/01/16/healthcare-aetna-hepatitisc-idUSL1N0UV1RJ20150116
Gilead gets FDA Orphan Designation for pulmonary arterial hypertension treatment:
http://www.accessdata.fda.gov/scripts/opdlisting/oopd/OOPD_Results_2.cfm?Index_Number=459114
Crazy wild buck of a stock! Yeeehaaaw! This will all be over post earnings when we will stay over $100 for good.
Go GILD
BBRY holding up above $10, surprisingly. Up over 5% from Tuesday's close before the false news.
Some positive spins to that story as well:
http://seekingalpha.com/article/2821616-blackberry-has-turned-down-multiple-buyout-offers
Harvard Pilgrim Health Care Picks Harvoni:
http://www.biocentury.com/dailynews/topstory/2015-01-15/two-more-payers-pick-harvoni
Gilead seems to be getting everyone but Express Scripts for their HCV genotype-1 treatment.
Humana opts for Gilead in hepatitis C drug battle:
http://www.modernhealthcare.com/article/20150114/NEWS/301149943/humana-opts-for-gilead-in-hepatitis-c-drug-battle
GILD
"CVS Health found that among the 65 million members covered by CVS Health's pharmacy benefit management business, prescription volume of Harvoni at eight weeks following its launch was roughly 2.5 times greater than Sovaldi's prescription rate eight weeks following its launch in December 2013. The number of Harvoni prescriptions at eight weeks totaled over 7,500, while Sovaldi's scripts totaled just more than 3,000 at the same point following its launch."
Less pills to take and more effective. Only pushback was the price but that didn't stop Harvoni from outselling Sovaldi eight weeks into launch. Who's gonna go with the older less effective solution for their health.
They'll eventually work out the pricing issues but Harvoni will still be Harvoni and Sovaldi will still be Sovaldi.
GILD
Yeah, that was a crazy ride too. Everyone was screaming that they're coming out with a wearable cam but usually some aspect of any new Apple hardware almost always gets leaked beforehand and there was nothing. Twitter has a new rumor almost every week.
Buying and holding on rumor runups is a suckers game. Those that rode the last 20 min momo on BBRY and took the money and ran today played it right.
Not enough time unless you were watching it all day or it went off on your scanner. It all happened in the last 20 mins of trading.
This kind of crazy fake news stuff I usually only see on OTC tickers.
There's a thought. Maybe big money stuck in it looking for a quick exit.
One of these guys, perhaps:
http://www.nasdaq.com/symbol/bbry/institutional-holdings
Definitely doesn't pass the sniff test in any case. Wonder if we will start seeing those "Class Action Lawsuit" PR's trickling on BBRY news stream on Friday if tomorrow ends in a bloodbath. Definitely won't open pretty.
Where did the rumor start? Anyone know? Originally came out of Reuters, I think:
http://arstechnica.com/gadgets/2015/01/samsung-wants-blackberry-in-potential-7-5-billion-takeover-deal-sources-say/
BlackBerry already made a Android security deal with Samsung late last year so I can see how someone can cook up a bogus but plausible Samsung acquisition story.
lol, I was just thinking that. Zero to 100 mph and back to zero in one day!
BlackBerry bats away Samsung purchase report:
http://www.cnbc.com/id/102276894
BBRY
Looks like we won that coin toss today thank goodness ;) You rolled a lot more into the Friday's than I did, though. Congrats!
Big time short squeeze on BBRY here! Went from below the SMA-200 to November 13th high break in minutes!
Crazy ride
Nearly 25% of BBRY float short:
http://shortsqueeze.com/?symbol=BBRY&submit=Short+Quote%99
Harvoni is outselling Sovaldi according to CVS data. I think GILD runs back up to recent highs leading into earnings.
Go GILD
Did Gilead Sciences' Sales Soar in Q4?
MF article here:
http://www.nasdaq.com/article/did-gilead-sciences-sales-soar-in-q4-cm432229
Be interesting to see how GILD moves leading up to earnings
Well, we know a lot can happen in a day on a biotech stock so it's not totally far fetched to speculate $100 by Friday on GILD giving the last few sessions.
Either way, I still think today's drop is overdone.
I'm right there with you. Too tempting to pass up they were so cheap. I'll either make a a nice profit again here or lose my ass.
IBB bouncing back now too with GILD so we'll see how this last 1.5 hours pans out.
Good Luck!
Definitely takes some conviction to hold but these kind of wild moves it what transfers money out of the smaller pockets into the deeper ones.
The SMA-200 area would take GILD down to around -10% from the Jan 9th high (where the shorts can no longer press the bid due to the uptick rule) and I bet a lot of money is sitting there waiting to cover or go long again.
No negative points regarding earnings guidance that I can tell. Only market "price war" speculation. Stock seems to have moved down on Credit Suisse issuing a "cautious" note regarding concerns over Hep-C drug pricing and this new daily low here is coinciding with the drop in the IBB.
Another overdone selloff on GILD further exaggerated by the shorts, no doubt, who appear to be trying to take it to the SMA-200 but I'm a buyer down here on this flush.